1996-2000: M.D., Memorial University of Newfoundland, St. John's, Newfoundland, Canada
1992-1996: B.S., Biochemistry, State University of New York – Geneseo College, Geneseo, NY
Neuroprotective therapies in Parkinson's disease
Behavioral changes in movement disorders
Nicotine in Parkinson's disease
Parkinson's disease and other movement disorders
Deep brain stimulation
Botulinum toxin injections
2005-present: Assistant Professor of Neurology, University of Vermont College of Medicine
2005-present: Attending Physician, Fletcher Allen Health Care, Burlington, VT
2005: Board certification in Neurology, American Board of Psychiatry & Neurology
2007: Board certification in the Subspecialty of Clinical Neurophysiology, American Board of Psychiatry & Neurology
2004-present: Medical Licensure, State of Vermont
2010: Parkinson Study Group - Mentored Clinical Research Award
2004: Huntington Mavor Memorial Award - Department of Neurology University of Vermont.
2004: Arnold P.Gold Foundation - Humanism and Excellence in Teaching Award
2003: Resident of the Year Award - Department of Neurology, University of Vermont
1999: Bruce A. Fraser Scholarship for academic achievement
1996: Tri-Beta Biology National Honor Society
1993: John Hablitz Memorial Scholarship for academic achievement
2010-present: Parkinson Study Group - Mentoring Committee
2009-present: Committee on Human Research in the Medical Sciences (UVM Institutional Review Board)
2009-present: Member, American Society for Experimental NeuroTherapeutics (ASENT)
2008-present: Member, Parkinson Study Group (PSG)
2008-present: Careers in Medicine - UVM Medical Student Advisor
2007-present: Member, International Society for Posture and Gait Research (ISPGR)
2006-present: Faculty Advisor, Student Interest Group in Neurology (SIGN)
2005-present: Senator, UVM Faculty Senate
2004-present: Member, Vermont State Medical Society
2004-present: Member, Movement Disorders Society (MDS)
2001-present: Member, Northern New England Neurological Society (NNENS)
2001-present: Member, American Academy of Neurology (AAN)
2011-present: A Randomized, Placebo-Controlled, Multicenter Study to Assess the Disease Modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA (NIC-PD). MJ Fox Foundation (KKS-135). PI: Oertel, W. Role: Co-investigator/United States PI.
2011-present: A Multicenter, Double Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease (FS-ZONE). NINDS (NS43128 (NET-PD) FS03-2010). Role: Site PI.
2010-present: Clinical Balance Impairment Associated with Huntington's Disease. Unfunded. PI: Jacobs, JV. Role: Co-PI.
2010-present: Nicotine in the Treatment of Impulsivity in Parkinson's Disease: A Pilot Study. Parkinson Sudy Group/Parkinson's Disease Foundation. Role: PI.
2007-present: Neuroexploratory Therapeutics in Parkinson's Diseases (NET-PD). A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects with Treated Parkinson's Disease (PD). Long-term Study-1 (LS-1). NIH/NINDS (NS43128). Site PI: Hamill, RW. Role: Enrolling sub-investigator.
Boyd JT, Ledez K. Decompression illness/Arterial gas embolism. Biller, J (Editor). Neurology of Internal Medicine. Lippincott, Williams & Wilkins. 2008.
Boyd JT, Poduri A. Guillain-Barre Syndrome. Schwartz, WM (Editor). The 5 Minute Pediatric Consult. 5th Edition. 2008.Report from a U.S. conference on essential tremor. Elble RJ et al; Tremor Research Group. Mov Disord. 2006 Dec; 21(12);2052-61. Consortium participant.
Murray TJ, Pryse-Phillips WE, Boyd JT. Toxic Damage to the Nervous System. Chapter 66. Noble, John (Editor). Textbook of Primary Care Medicine. 3rd Edition. St. Louis : Mosby, 2001To see more of Dr. Boyd's publications, please visit PubMed.